Atavistik Bio
PrivateLast Round
Series B
Mar 5, 2026
Total Funding Raised
$460M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Atavistik Bio is a biopharmaceutical company that discovers and develops precision allosteric small molecule therapeutics for metabolic diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atavistik Bio Comparables
Compare Atavistik Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alterome Therapeutics | 88% | |
| HotSpot Therapeutics | 86% | |
| Frontier Medicines | 83% |
Atavistik Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 5, 2026 | ||||
| Series B | Dec 18, 2025 | ||||
| Series A Extension | Dec 19, 2023 | ||||
| Series A | Aug 24, 2021 |
Key People
Founding team and executive leadership
Atavistik Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series A, Series A Extension |
| RA Capital Management | Series B |
| Lux Capital | Series A, Series B, Series A Extension |
| The Chernin Group | Series A, Series A Extension |
| Nextech Invest | Series A, Series B, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 109% MoM, reaching 4.1K.
- Mar 16, 2026
Agent ZE74-0282 is currently in Phase I clinical trials.
Recent news
Latest coverage and updates
- partners_withSep 25, 2026
Atavistik Bio, Inc. partnered with Genentech, Inc. on Sep 21st '26.
- partners_withSep 25, 2026
Atavistik Bio, Inc. partnered with Novo Nordisk A/S on Sep 21st '26.
- is_developingSep 24, 2026
Atavistik Bio, Inc. is developing treatments for rare blood disorders on Sep 24th '26.
- is_developingSep 24, 2026
Atavistik Bio, Inc. is developing oral treatments for cardiovascular, kidney and metabolic diseases on Sep 24th '26.
- is_developingSep 24, 2026
Atavistik Bio, Inc. is developing novel allosteric therapeutics on Sep 24th '26.
Atavistik Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Atavistik Bio's valuation, stock price, and market status.
Is Atavistik a public or private company?
Atavistik is a private company.
What is the current stock price of Atavistik?
Atavistik is a private company with no public stock price. No recent secondary market data is available.
How much is Atavistik worth (valuation)?
Valuation information for Atavistik is not publicly available.
Can I buy Atavistik stock?
Atavistik shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Atavistik's last funding round?
Atavistik's most recent funding round was Series B on March 5, 2026.
Who are the main investors in Atavistik?
Key investors in Atavistik include The Column Group, RA Capital Management, Lux Capital, The Chernin Group, Nextech Invest.
Will Atavistik IPO soon?
No public IPO plans have been announced for Atavistik.
How can I track Atavistik secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Atavistik's secondary market activity and sign up for updates.